
Annual report 2024
added 03-07-2026
Trinity Biotech plc EPS Ratio 2011-2026 | TRIB
EPS is a measure used to assess the financial stability and profitability of a company. EPS (Earnings Per Share) represents the company's net income divided by the number of its outstanding shares. This measure allows investors and analysts to evaluate the return on investment in the company's stock and compare it to other companies in the industry.
The term earnings per share (EPS) represents the portion of a company's earnings, net of taxes and preferred stock dividends, that is allocated to each share of common stock. The figure can be calculated simply by dividing net income earned in a given reporting period (usually quarterly or annually) by the total number of shares outstanding during the same term. Because the number of shares outstanding can fluctuate, a weighted average is typically used.
Calculated as:
EPS = (Net Income - Dividends on Preffered Stock) / Average Outstanding shares[1]
EPS can be calculated as a simple ratio of net income to shares, or in various variations, such as diluted EPS, which takes into account the potential issuance of new shares or convertible securities.
A high EPS ratio usually indicates that the company has good profitability and efficiency in utilizing its assets. However, other factors such as sales growth, debt burden, and the company's competitive position should also be considered.
EPS ratio is an important indicator for investors when making decisions to buy or sell a company's stock. It is also used by analysts to assess the financial condition of the company and its potential for growth and development.
Quarterly EPS Ratio Trinity Biotech plc
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.8 | - | - | - | 4.1 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 4.1 | 2.8 | 3.45 |
References
- Khan, T. R., Islam, M. R., Choudhury, T. T., & Adnan, A. M. (2014). How earning per share (EPS) affects on share price and firm value.
EPS Ratio of other stocks in the Diagnostics research industry
| Issuer | EPS Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Centogene N.V.
CNTG
|
-2.06 | - | -6.23 % | $ 30.6 M | ||
|
ICON Public Limited Company
ICLR
|
9.6 | $ 98.33 | 0.9 % | $ 8.11 B | ||
|
Akumin
AKU
|
-1.75 | - | -17.87 % | $ 25.9 M | ||
|
Aspira Women's Health
AWH
|
-0.23 | - | -6.19 % | $ 10.5 M | ||
|
Brainsway Ltd.
BWAY
|
-0.24 | $ 13.71 | -0.22 % | $ 99.4 M | ||
|
Charles River Laboratories International
CRL
|
-2.91 | $ 155.46 | 1.83 % | $ 7.71 B | ||
|
Bioventus
BVS
|
0.34 | $ 8.62 | 0.23 % | $ 574 M | ||
|
DexCom
DXCM
|
2.14 | $ 64.24 | -1.56 % | $ 25.1 B | ||
|
Castle Biosciences
CSTL
|
0.66 | $ 25.56 | 0.95 % | $ 710 M | ||
|
CareDx, Inc
CDNA
|
-0.4 | $ 17.01 | 3.4 % | $ 906 M | ||
|
Accelerate Diagnostics
AXDX
|
-0.14 | - | -61.36 % | $ 2.46 M | ||
|
Exact Sciences Corporation
EXAS
|
-1.1 | $ 103.57 | 0.29 % | $ 19.5 B | ||
|
Guardant Health
GH
|
-3.32 | $ 85.49 | 1.75 % | $ 10.7 B | ||
|
Global Cord Blood Corporation
CO
|
4.12 | - | - | $ 399 M | ||
|
Genetic Technologies Limited
GENE
|
-0.08 | - | - | $ 7.1 B | ||
|
Genetron Holdings Limited
GTH
|
-1.08 | - | 0.12 % | $ 80.1 M | ||
|
Fulgent Genetics
FLGT
|
-1.41 | $ 14.77 | 0.61 % | $ 447 M | ||
|
Biodesix
BDSX
|
-0.33 | $ 17.88 | -6.63 % | $ 2.32 B | ||
|
Anixa Biosciences
ANIX
|
-0.34 | $ 2.83 | -1.05 % | $ 91.8 K | ||
|
Danaher Corporation
DHR
|
5.07 | $ 187.32 | 0.57 % | $ 134 B | ||
|
IQVIA Holdings
IQV
|
7.91 | $ 164.72 | 1.1 % | $ 28.3 B | ||
|
Biocept
BIOC
|
-1.89 | - | -13.05 % | $ 7.29 M | ||
|
Heska Corporation
HSKA
|
-1.92 | - | - | $ 1.31 B | ||
|
HTG Molecular Diagnostics
HTGM
|
-24.3 | - | -20.0 % | $ 1.06 M | ||
|
Illumina
ILMN
|
-7.69 | $ 118.94 | 2.92 % | $ 18.9 B | ||
|
Quest Diagnostics Incorporated
DGX
|
8.87 | $ 199.7 | -0.46 % | $ 22.2 B | ||
|
QIAGEN N.V.
QGEN
|
0.38 | - | - | $ 10.6 B | ||
|
Agilent Technologies
A
|
3.98 | $ 111.51 | -0.06 % | $ 33.9 B | ||
|
BioNano Genomics
BNGO
|
-88.1 | $ 1.11 | -0.89 % | $ 1.41 M | ||
|
DarioHealth Corp.
DRIO
|
1.93 | $ 9.0 | -0.99 % | $ 255 M | ||
|
Neogen Corporation
NEOG
|
-5.03 | $ 9.09 | -2.78 % | $ 1.97 B | ||
|
National Research Corporation
NRC
|
50 | $ 16.52 | 0.12 % | $ 370 M | ||
|
Chembio Diagnostics
CEMI
|
-0.72 | - | 0.22 % | $ 16.8 M | ||
|
Check-Cap Ltd.
CHEK
|
4.3 | - | - | $ 9.42 M | ||
|
Pacific Biosciences of California
PACB
|
-1.82 | $ 1.33 | 4.72 % | $ 399 M | ||
|
Co-Diagnostics
CODX
|
-1.2 | - | - | $ 79.8 M | ||
|
Medpace Holdings
MEDP
|
15.6 | $ 450.41 | 1.48 % | $ 13 B | ||
|
Celcuity
CELC
|
-2.83 | $ 114.22 | 3.11 % | $ 4.51 B | ||
|
DermTech
DMTK
|
-3.09 | - | -11.32 % | $ 2.94 M | ||
|
Mettler-Toledo International
MTD
|
42.2 | $ 1 173.74 | 0.49 % | $ 24.2 B | ||
|
Personalis
PSNL
|
-1.37 | $ 6.72 | 1.97 % | $ 398 M | ||
|
NeoGenomics
NEO
|
-0.84 | $ 7.88 | -1.25 % | $ 1.01 B | ||
|
Enzo Biochem
ENZ
|
-0.51 | - | -8.98 % | $ 14.8 K | ||
|
Natera
NTRA
|
-5.57 | $ 187.85 | -1.29 % | $ 18.5 B | ||
|
Sotera Health Company
SHC
|
0.27 | $ 13.42 | 0.71 % | $ 3.81 B | ||
|
Invitae Corporation
NVTA
|
-13.2 | - | - | $ 21.2 M | ||
|
OPKO Health
OPK
|
0.02 | $ 1.19 | 2.59 % | $ 826 M |